Eton Pharma Q4 product sales $21.3M (+83% YoY); guides FY26 rev >$110M, 30%+ EBITDA margin

Eton Pharmaceuticals, Inc.

Q4 product sales $21.3M (+83% YoY); GAAP diluted EPS $0.05, non-GAAP diluted EPS $0.19; Adj. EBITDA $6.2M
Launched DESMODA (first FDA-approved desmopressin oral solution) on March 9, 2026
Acquired U.S. rights to Orphan Drug HEMANGEOL; relaunch May 1, 2026; accretive to 2026 earnings
FY 2026 guidance: revenue >$110M, Adj. EBITDA margin >30%
Cash $25.9M at Dec 31, 2025; net income $1.5M vs loss $5.4M prior year

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.